Clinical Trials Directory

Trials / Recruiting

RecruitingNCT07229196

Clinical Trial in Hypertensive Patients Comparing Two Cardiorespiratory Exercise Protocols, Low-volume Sprint Interval Training (SIT) Versus Moderate-intensity Continuous Training (MICT), to Evaluate Decreases in Ambulatory Blood Pressure and Other Clinical Variables.

Status
Recruiting
Phase
N/A
Study type
Interventional
Enrollment
20 (estimated)
Sponsor
Unidad Enfermedades Cardiometabolicas- Hospital Interzonal General Agudos San Martin de La Plata · Academic / Other
Sex
All
Age
30 Years – 59 Years
Healthy volunteers
Not accepted

Summary

This randomized clinical trial aims to compare two cardiorespiratory exercise training protocols - Sprint Interval Training (SIT), characterized by short, maximal-intensity efforts, versus Moderate-Intensity Continuous Training (MICT) - in patients with arterial hypertension. The primary objective is to evaluate the impact of both interventions on 24-hour ambulatory systolic blood pressure (ABPM) after a 12-week training period. Secondary outcomes include diastolic, daytime, and nighttime blood pressure, metabolic and hemodynamic parameters, body composition, and serum myokine levels (IL-6 and α-CGRP). Participants aged 30-59 years with diagnosed hypertension but without high cardiovascular risk will be recruited from the Cardio-Metabolic Disease Unit of Hospital San Martín (La Plata, Argentina). After a two-week familiarization period, eligible participants will be randomized to SIT or MICT groups. The intervention will last 12 weeks, with three supervised sessions per week. The study will provide valuable information about the effectiveness, safety, and clinical applicability of brief, high-intensity exercise for blood pressure control in hypertensive patients.

Detailed description

Introduction Cardiovascular disease remains the leading cause of mortality worldwide, with hypertension as a major modifiable risk factor. Exercise is a key non-pharmacological strategy for blood pressure management. While moderate-intensity continuous training (MICT) is well established, Sprint Interval Training (SIT) - characterized by short (10-30 s) bursts of maximal effort - has shown promising metabolic and cardiovascular benefits with significantly shorter session durations. Despite growing interest, few clinical trials have evaluated SIT in hypertensive populations using ambulatory blood pressure monitoring (ABPM), which provides better prognostic information than office measurements. Furthermore, the biological mechanisms underlying exercise-induced benefits may involve myokines such as interleukin-6 (IL-6) and α-calcitonin gene-related peptide (α-CGRP), both associated with improved cardiometabolic health. Objectives Primary objective: To compare the effect of SIT versus MICT on 24-hour systolic ambulatory blood pressure after 12 weeks of structured exercise. Secondary objectives: Assess changes in diastolic, daytime, and nighttime ambulatory blood pressure. Evaluate office BP, anthropometric variables (weight, waist circumference, body fat percentage), and metabolic profile (lipids, glucose, TG/HDL ratio). Assess changes in maximal oxygen consumption (VO₂max), non-invasive hemodynamic parameters, and handgrip strength. Determine post-training serum concentrations of IL-6 and α-CGRP as biomarkers of exercise response. Analyze acute hemodynamic responses and adherence to training. Materials and Methods Design: Open-label, randomized, parallel-group clinical trial with pre- and post-intervention evaluations. Population: Hypertensive adults (30-59 years) attending the Cardio-Metabolic Disease Unit of Hospital San Martín (La Plata, Argentina). Inclusion criteria: Confirmed hypertension (treated or untreated). BMI 18.5-34.9 kg/m². Exclusion criteria: Office BP ≥160/100 mmHg. Diabetes, chronic kidney disease (eGFR \<60 mL/min), coronary or cerebrovascular disease, pregnancy, or severe comorbidities. Intervention: Participants undergo a 2-week familiarization phase before randomization into two groups: MICT group: Continuous cycling at 50-70% of VO₂max, 15-30 minutes per session. SIT group: 2-4 maximal 20-30-second cycling sprints (≥100% VO₂max) with recovery intervals (2-4 min), total duration ≤15 minutes per session. Both groups train three times per week for 12 weeks, under professional supervision. Blood pressure, heart rate, and oxygen saturation will be monitored during sessions for safety. Evaluations: At baseline and post-intervention: Office and 24-hour ABPM measurements. Anthropometry and laboratory tests (lipid profile, glucose, IL-6, α-CGRP via ELISA). Impedance cardiography and pulse wave velocity for non-invasive hemodynamics. Graded exercise test to determine VO₂max. Handgrip strength test. Sample size: A total of 14-20 participants (7-10 per group) are required to detect a 5 mmHg difference in 24-hour systolic BP with 80% power and α=0.05. Statistical analysis: Between-group comparisons will use t-tests or Wilcoxon rank-sum tests depending on data distribution. Within-group pre/post differences will be analyzed with paired tests. Analyses will follow the intention-to-treat principle, with additional per-protocol analysis for participants achieving ≥75% adherence. Ethics: The study is classified as minimal risk and adheres to the Declaration of Helsinki (2024). Approved by the Ethics Committee of Hospital San Martín de La Plata (Reg. No. 070/2019). All participants will provide written informed consent.

Conditions

Interventions

TypeNameDescription
BEHAVIORALSIT group: 2-4 maximal 20-30-second cycling sprints (≥100% VO₂max) with recovery intervals (2-4 min), total duration ≤15 minutes per session.SIT group: 2-4 maximal 20-30-second cycling sprints (≥100% VO₂max) with recovery intervals (2-4 min), total duration ≤15 minutes per session. Three times per week for 12 weeks
BEHAVIORALMICT group: Continuous cycling at 50-70% of VO₂max, 15-30 minutes per session.MICT group: Continuous cycling at 50-70% of VO₂max, 15-30 minutes per session. three times per week for 12 week

Timeline

Start date
2025-04-29
Primary completion
2026-11-01
Completion
2027-01-01
First posted
2025-11-14
Last updated
2025-11-14

Locations

1 site across 1 country: Argentina

Source: ClinicalTrials.gov record NCT07229196. Inclusion in this directory is not an endorsement.